Journal of Hospice and Palliative Care

  • 제13권4호
  • /
  • Pages.252-256
  • /
  • 2010
  • /
  • 2765-3072(pISSN)
  • /
  • 2765-3080(eISSN)
한국호스피스완화의료학회 (Korean Society for Hospice and Palliative Care)
권호 표지

말기암환자에서 불응성 호흡곤란 완화를 위한 Furosemide 흡입치료 -대한가정의학회 완화의학연구회 세미나에 기초한-

Applying Inhaled Furosemide for Refractory Breathlessness in Terminally-ill Cancer Patients - Based on Seminar of Palliative Medicine Research Group, The Korean Academy of Family Medicine -

  • Hwang, In-Cheol (Department of Family Medicine, Gachon University Gil Hospital) ;
  • Lee, Min-Kyu (Department of Family Medicine, Gachon University Gil Hospital) ;
  • Kim, Kyoung-Kon (Department of Family Medicine, Gachon University Gil Hospital) ;
  • Lee, Kyoung-Sik (Department of Family Medicine, Gachon University Gil Hospital) ;
  • Suh, Heuy-Sun (Department of Family Medicine, Gachon University Gil Hospital) ;
  • 투고 : 2010.06.24
  • 심사 : 2010.10.22
  • 발행 : 2010.12.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

말기 암환자에서의 호흡곤란은 매우 흔하면서도 고통스러운 증상이다. 불응성 호흡곤란은 호흡곤란을 야기시키는 가역적인 원인들이 배제되고 기존의 고식적인 치료에 반응하지 않는 상태로 정의할 수 있으며, 일반적으로 아편유사제와 벤조디아제핀이 사용된다. 대한 가정의학회 완화의학연구회에서는 호흡곤란의 원인이 다른 2명의 증례에서 사용한 furosemide 흡입치료에 대해 논의하였다. Furosemide 흡입치료는 비교적 최근에 대두된 것으로 아직까지 그 효과나 기전이 불명확하여 임상에서 일률적으로 사용하기에는 무리가 있지만, 뚜렷한 폐쇄성 기도병변이 없는 불응성 호흡곤란 환자에서는 고려해 볼 수 있겠다. 본 증례토론을 통해 국내 완화의료 종사자들과 furosemide 흡입치료 경험을 공유하고, 아울러 향후 이 주제에 대한 연구의 방향을 제시하고자 한다.

Breathlessness is a frequent and distressing symptom in terminal cancer patients. Refractory breathlessness is defined as a state that does not respond to conventional disease-specific therapy with an exclusion of reversible underlying causes, and the main classes of symptomatic drug treatments include opioids and benzodiazepines. Korean Family Medicine Palliative Medicine Research Group discussed two terminal cancer patients in whom severe breathlessness with different causes were treated with inhalation of nebulized furosemide, which is an emerging option of palliative treatment. It still remains unclear how it becomes effective or how much it is effective, therefore, its routine use seems to be somewhat early. Nevertherless, if a patient with intractable breathlessness does not have a marked obstructive airway lesion, its use should be considered. Based on the discussion in the seminar, we want to share our experience of the application of inhaled furosemide with other palliative care practitioners and strongly recommend further research on this topic in the future.

키워드

참고문헌

  1. Mercadante S, Casuccio A, Fulfaro F. The course of symptom frequency and intensity in advanced cancer patients followed at home. J Pain Symptom Manage 2000;20(2):104-12. https://doi.org/10.1016/S0885-3924(00)00160-3
  2. Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Chest 1986;89(2):234-6. https://doi.org/10.1378/chest.89.2.234
  3. Cachia E, Ahmedzai SH. Breathlessness in cancer patients. Eur J Cancer 2008;44(8):1116-23. https://doi.org/10.1016/j.ejca.2008.03.004
  4. Thomas JR, von Gunten CF. Clinical management of dyspnoea. Lancet Oncol 2002;3(4):223-8. https://doi.org/10.1016/S1470-2045(02)00713-1
  5. Kohara H, Ueoka H, Aoe K, Maeda T, Takeyama H, Saito R, et al. Effect of nebulized furosemide in terminally ill cancer patients with dyspnea. J Pain Symptom Manage 2003;26(4):962-7. https://doi.org/10.1016/S0885-3924(03)00322-1
  6. Dorman S, Byrne A, Edwards A. Which measurement scales should we use to measure breathlessness in palliative care? A systematic review. Palliat Med 2007;21(3):177-91. https://doi.org/10.1177/0269216307076398
  7. Newton PJ, Davidson PM, Macdonald P, Ollerton R, Krum H. Nebulized furosemide for the management of dyspnea: does the evidence support its use? J Pain Symptom Manage 2008;36(4):424-41. https://doi.org/10.1016/j.jpainsymman.2007.10.017
  8. Bianco S, Vaghi A, Robuschi M, Pasargiklian M. Prevention of exercise-induced bronchoconstriction by inhaled frusemide. Lancet 1988;2(8605):252-5.
  9. Stone P, Kurowska A, Tookman A. Nebulized frusemide for dyspnoea. Palliat Med 1994;8(3):258. https://doi.org/10.1177/026921639400800315
  10. Ben-Aharon I, Gafter-Gvili A, Paul M, Leibovici L, Stemmer SM. Interventions for alleviating cancer-related dyspnea: a systematic review. J Clin Oncol 2008;26(14):2396-404. https://doi.org/10.1200/JCO.2007.15.5796
  11. Wilcock A, Walton A, Manderson C, Feathers L, El Khoury B, Lewis M, et al. Randomised, placebo controlled trial of nebulised furosemide for breathlessness in patients with cancer. Thorax 2008;63(10):872-5. https://doi.org/10.1136/thx.2007.091538
  12. American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med 1999;159(1):321-40. https://doi.org/10.1164/ajrccm.159.1.ats898
  13. Gwak JI, Suh SY. The assessment tools in palliative medicine. Korean J Hosp Palliat Care 2009;12(4):177-93.